Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**MX100A** is Genescient's botanical dietary-supplement program, marketed as **Geneaire ReBuilder**, for mild to moderate Alzheimer's disease. It is described as a multi-component botanical mixture developed using transgenic *Drosophila* models and machine-learning analyses to address multiple aging- and dementia-related biological pathways. A completed 12-month, double-blind, placebo-controlled pilot study in 50 participants evaluated ReBuilder added to existing standard Alzheimer's disease regimens; Genescient reported stabilization or slowing of cognitive decline and stated that further study was warranted. ([genescient.com](https://www.genescient.com/botanical-mixture-stabilizes-cognitive-function-in-patients-with-mild-and-moderate-alzheimers-disease/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MX100A.